Effectiveness of Ultrasound-guided Scalp Block for Supratentorial Craniotomy
Effectiveness of Ultrasound-guided Scalp Block for Supratentorial Craniotomy: a Randomised Controlled Trial
University Malaysia Sarawak
60 participants
Apr 1, 2024
INTERVENTIONAL
Conditions
Summary
Pain management in patients undergoing neurosurgery is a very important issue. The effectiveness of USG-guided scalp blocks for pain management in craniotomy surgery is currently not known. The purpose of this clinical trial is to evaluate the effectiveness of ultrasound-guided scalp block when performed in patients who undergo supratentorial craniotomies.
Eligibility
Inclusion Criteria1
- All American Society of Anesthesia class I to III patients undergoing elective supratentorial craniotomies under general anaesthesia.
Exclusion Criteria10
- Refusal to participate in the study
- Contraindications to the performance of scalp block, such as local infections
- Allergy to ropivacaine hydrochloride
- Age < 18 years old
- Undergoing emergency craniotomies, posterior fossa surgery, or burr holes surgery
- Pre-existing chronic pain (defined as persistent or recurrent pain lasting > 3 months)
- History of drug addiction (illicit substances and opioids use) or chronic alcohol abuse
- Presence of uncontrolled systemic arterial hypertension, severe cardiovascular disease, severe kidney or severe liver diseases
- Predicted to require postoperative ventilation in the intensive care unit
- Psychiatric disorders, serious neurological diseases, or reduced consciousness GCS < 14
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Scalp block will be performed under USG guidance, using the technique described by Tsan et al. The block needle used will be an echogenic block needle, with a length of 50 mm, and a diameter of 22 G. Trained personnel comprising of the investigators in this study will perform the scalp block. Using ultrasound to identify landmarks, ropivacaine 0.375% will be administered in volumes of 1.5 ml to 3 ml. The nerves targeted will be the supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, greater auricular, lesser occipital, greater occipital and third occipital nerves.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06127628